Sana Biotechnology (SANA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $2.47, +6.22% vs the prior close of $2.33.
- Volume 2.92M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SANA jumps 6.2% to $2.47. Closed at $2.47, +6.22% vs the prior close of $2.33. Day range $2.35–$2.51, opened at $2.36.
SANA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — SANA jumps 6.2% to $2.47
- Closed at $2.47, +6.22% vs the prior close of $2.33. Day range $2.35–$2.51, opened at $2.36.
- Volume was 2.92M shares, 0.9x its 50-day average of 3.38M.
- Price is -25.4% vs its 50-day average ($3.32) and -29.3% vs its 200-day average ($3.50).
- 52-week range $2.32–$6.55; today's close sits at 4% of that range, 62.2% below the 52-week high.
Oct 14, 2026 — SANA slides 3.3% to $2.33, a 52-week low, 4 down days in a row
- Closed at $2.33, -3.32% vs the prior close of $2.41. Day range $2.32–$2.43, opened at $2.37.
- Volume was 2.76M shares, 0.8x its 50-day average of 3.36M.
- Price is -30.2% vs its 50-day average ($3.34) and -33.6% vs its 200-day average ($3.51).
- 52-week range $2.32–$6.55; today's close sits at 0% of that range, 64.4% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — SANA slides 8.0% to $2.41, a 52-week low, 3 down days in a row
- Closed at $2.41, -8.02% vs the prior close of $2.62. Day range $2.37–$2.63, opened at $2.60.
- Volume was 4.90M shares, 1.5x its 50-day average of 3.31M.
- Price is -28.2% vs its 50-day average ($3.36) and -31.6% vs its 200-day average ($3.52).
- 52-week range $2.37–$6.55; today's close sits at 1% of that range, 63.2% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — SANA slides 6.1% to $2.62, a 52-week low
- Closed at $2.62, -6.09% vs the prior close of $2.79. Day range $2.59–$2.77, opened at $2.77.
- Volume was 2.67M shares, 0.8x its 50-day average of 3.30M.
- Price is -22.4% vs its 50-day average ($3.37) and -25.8% vs its 200-day average ($3.53).
- 52-week range $2.59–$6.55; today's close sits at 1% of that range, 60.0% below the 52-week high.
Oct 9, 2026 — SANA ends flat (+0.0%) to $2.79
- Closed at $2.79, +0.00% vs the prior close of $2.79. Day range $2.77–$2.87, opened at $2.79.
- Volume was 2.92M shares, 0.9x its 50-day average of 3.28M.
- Price is -17.6% vs its 50-day average ($3.38) and -21.2% vs its 200-day average ($3.54).
- 52-week range $2.61–$6.55; today's close sits at 5% of that range, 57.4% below the 52-week high.
Oct 8, 2026 — SANA rises 2.6% to $2.79
- Closed at $2.79, +2.57% vs the prior close of $2.72. Day range $2.66–$2.81, opened at $2.72.
- Volume was 4.51M shares, 1.4x its 50-day average of 3.25M.
- Price is -17.8% vs its 50-day average ($3.39) and -21.4% vs its 200-day average ($3.55).
- 52-week range $2.61–$6.55; today's close sits at 5% of that range, 57.4% below the 52-week high.
Oct 7, 2026 — SANA dips 1.1% to $2.72, a 3-month low, 5 down days in a row
- Closed at $2.72, -1.09% vs the prior close of $2.75. Day range $2.70–$2.85, opened at $2.71.
- Volume was 4.31M shares, 1.3x its 50-day average of 3.24M.
- Price is -20.0% vs its 50-day average ($3.40) and -23.6% vs its 200-day average ($3.56).
- 52-week range $2.61–$6.55; today's close sits at 3% of that range, 58.5% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — SANA slides 4.5% to $2.75, a 3-month low, 4 down days in a row
- Closed at $2.75, -4.51% vs the prior close of $2.88. Day range $2.74–$2.97, opened at $2.94.
- Volume was 3.76M shares, 1.2x its 50-day average of 3.23M.
- Price is -19.4% vs its 50-day average ($3.41) and -22.9% vs its 200-day average ($3.57).
- 52-week range $2.61–$6.55; today's close sits at 4% of that range, 58.0% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — SANA dips 0.3% to $2.88, a 3-month low, 3 down days in a row
- Closed at $2.88, -0.35% vs the prior close of $2.89. Day range $2.82–$2.93, opened at $2.90.
- Volume was 5.39M shares, 1.7x its 50-day average of 3.17M.
- Price is -15.9% vs its 50-day average ($3.42) and -19.5% vs its 200-day average ($3.58).
- 52-week range $2.61–$6.55; today's close sits at 7% of that range, 56.0% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — SANA ends flat (+0.0%) to $2.89
- Closed at $2.89, +0.00% vs the prior close of $2.89. Day range $2.86–$3.00, opened at $2.95.
- Volume was 3.50M shares, 1.1x its 50-day average of 3.15M.
- Price is -15.7% vs its 50-day average ($3.43) and -19.4% vs its 200-day average ($3.59).
- 52-week range $2.61–$6.55; today's close sits at 7% of that range, 55.9% below the 52-week high.
SANA latest news & SEC filings
Every SEC filing by or about SANA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bishop Hans Edgar received an award of 8,680 shares on Oct 5, 2026; now holds 5,863,480
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 27, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$63.63M (prior year -$93.80M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.22 (prior year -$0.39) (loss narrowed vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade SANA
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 3, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.69% (largest 8.0%).
- Liquidity: about 3.84M shares (≈$9.50M) trade per day on average.
- 52-week position: $2.47 vs a range of $2.32–$6.55 (4% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 8, 2026; 10-Q Aug 10, 2026; 8-K Aug 10, 2026.
- Share count: 299.36M shares outstanding (Aug 3, 2026), +25.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
SANA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 2.36 | 2.51 | 2.35 | 2.47 | 2.92M |
| Oct 14, 2026 | 2.37 | 2.43 | 2.32 | 2.33 | 2.76M |
| Oct 13, 2026 | 2.60 | 2.63 | 2.37 | 2.41 | 4.90M |
| Oct 12, 2026 | 2.77 | 2.77 | 2.59 | 2.62 | 2.67M |
| Oct 9, 2026 | 2.79 | 2.87 | 2.77 | 2.79 | 2.92M |
| Oct 8, 2026 | 2.72 | 2.81 | 2.66 | 2.79 | 4.51M |
| Oct 7, 2026 | 2.71 | 2.85 | 2.70 | 2.72 | 4.31M |
| Oct 6, 2026 | 2.94 | 2.97 | 2.74 | 2.75 | 3.76M |
| Oct 5, 2026 | 2.90 | 2.93 | 2.82 | 2.88 | 5.39M |
| Oct 2, 2026 | 2.95 | 3.00 | 2.86 | 2.89 | 3.50M |
| Oct 1, 2026 | 2.89 | 3.05 | 2.85 | 2.89 | 3.76M |
| Sep 30, 2026 | 2.97 | 3.05 | 2.86 | 2.91 | 3.25M |
| Sep 29, 2026 | 2.94 | 3.06 | 2.89 | 2.91 | 3.04M |
| Sep 28, 2026 | 2.92 | 2.98 | 2.86 | 2.93 | 2.26M |
| Sep 25, 2026 | 2.96 | 3.00 | 2.90 | 2.94 | 2.88M |
| Sep 24, 2026 | 3.04 | 3.05 | 2.88 | 2.96 | 3.51M |
| Sep 23, 2026 | 3.33 | 3.33 | 3.01 | 3.08 | 3.84M |
| Sep 22, 2026 | 3.15 | 3.36 | 3.10 | 3.33 | 7.17M |
| Sep 21, 2026 | 3.14 | 3.16 | 3.04 | 3.10 | 2.00M |
| Sep 18, 2026 | 3.09 | 3.11 | 3.02 | 3.10 | 7.41M |
About Sana Biotechnology
Sana Biotechnology (SANA) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SEATTLE, WA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1770121.
SANA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Joshua H. Bilenker | Director | Jun 5, 2026 |
| Hans Edgar Bishop | Director | Jul 7, 2026 |
| Steve Harr | President & CEO | Mar 10, 2026 |
| Richard Mulligan | Director | Jun 5, 2026 |
| Robert Nelsen | Director | Jun 5, 2026 |
| Alise Reicin | Director | Jun 5, 2026 |
| Robert L. Rosiello | Director | Jun 5, 2026 |
| Michelle Seitz | Director | Jun 5, 2026 |
| Patrick Y Yang | Director | Jun 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Steve Harr | President & CEO | Mar 10, 2026 |
| Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | Aug 27, 2026 |
| Brian Piper | EVP, Chief Financial Officer | Feb 18, 2026 |
| Susan D. Wyrick | See Remarks | Mar 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
SANA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-244.17M | -0.96 | $-143.83M |
| Dec 31, 2024 | — | $-266.76M | -1.16 | $-223.15M |
| Dec 31, 2023 | — | $-283.25M | -1.46 | $-253.58M |
| Dec 31, 2022 | — | $-269.48M | -1.43 | $-290.05M |
| Dec 31, 2021 | — | $-355.93M | -2.14 | $-251.05M |
Latest balance sheet: total assets $431.52M, total liabilities $276.95M, cash $57.07M (as of Jun 30, 2026).
SANA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $3.61 |
| May 11, 2026 | 8-K Item 2.02 (results) | $3.56 |
| Mar 3, 2026 | 8-K Item 2.02 (results) | $3.93 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $4.05 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $2.92 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $4.25 |
| May 8, 2025 | 8-K Item 2.02 (results) | $1.81 |
| Mar 17, 2025 | 8-K Item 2.02 (results) | $2.77 |
| Nov 8, 2024 | 8-K Item 2.02 (results) | $3.01 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on SANA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.